House passes compounding‑pharmacy bill after prolonged debate over safety clause, definitions

After extended floor debate on March 12, the Colorado House passed House Bill 12‑62, a measure that clarifies the state’s approach to compounding pharmacies and codifies distinctions related to 503A and 503B compounding.

Representative Stewart (sponsor) said the bill protects patient access in Colorado and nationwide, noting that one Colorado facility supplies concentrated formulations to children’s hospitals across the country. "This is really important to healthcare access within the state of Colorado," the sponsor said.

Floor debate was lengthy and sometimes tense. Representative Johnson pressed for a petition clause or delay to allow more stakeholder alignment, saying the measure had swung positions repeatedly during drafting and that more time could prevent litigation or a special session. "Adding a petition allows 90 more days ... so we don't have to come back in a special session or see a lawsuit," Johnson said.

Sponsors and other proponents argued the bill responds to an urgent access problem driven by changes in other states and federal rules; opponents said statutory fixes could limit state flexibility and urged more review. Multiple proposed amendments — including exclusions for veterinarians or agriculture and placing the policy in a petition clause — were debated and defeated on the floor. Sponsors indicated they would strip manufacturer liability from the bill in response to testimony; that amendment was accepted.

After recorded votes on several committee‑of‑the‑whole amendments (most failed) and further debate, the House adopted the committee report and passed House Bill 12‑62 on the floor.